To evaluate the immunogenicity and safety of an inactivated H7N9 vaccine with and without AS03 adjuvant , as well as mixed vaccine schedules that included sequential administration of AS03 - and MF59-containing formulations and of adjuvanted and unadjuvanted formulations .